The objective of our research is to investigate a new series of 1-(diarylmethyl)-1H-1,2,4-triazoles and 1-(diarylmethyl)-1H-imidazoles as a novel class of antimitotic compounds with an interesting biochemical profile particularly as tubulin-targeting agents and aromatase inhibitors for the treatment of breast cancer. This evidence concerns the gene CYP19A1 and breast carcinoma.